KOE:950220
NeoImmuneTech, Inc. · KOE · Healthcare · KRW · FY for 2025
Figures on this page computed 2026-11-08 13:38 UTC
Last close
n/aKRW
Market data
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
- Computed from the filing for 2025
-81.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-33531.4%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
-34003.6%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.18Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- KRW
- computed
Returns on capital is the furthest below its sector's middle: 0.13 against 0.25 on the market's range.
- Growth22.2%62 of 100, above its sector
- Returns on capital-81.7%13 of 100, below its sector
- Margins100.0%25 of 100, below its sector
- Price0.1x48 of 100, above its sector
- Safety0.1851 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
All from 100
lens 2 of 9Sales
55.7Shares in issue
4.8- Profit, where the first year is 100: n/aNot enough filed years carry this line for it to be drawn. No line is drawn flat in its place.
Sales is at 56, Shares in issue is at 5, against 100 in 2018.
Sales is at 56, Shares in issue is at 5, against 100 in 2018.
Every figure in this lens
Except where said otherwise: Computed from the filing for 2025
Sales, where the first year is 10056
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
Profit, where the first year is 100n/a
Not held.
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW
Shares in issue, where the first year is 1005
- Source
- computed
- Statement
- income
- Fiscal year
- 2025
- Reported in
- KRW